Health China

Landmark study in the lancet oncology shows Xeloda reduces early breast cancer recurrence

Large, independent phase III randomised study in women with early breast cancer shows that adding Xeloda (capecitabine) to a treatment regimen containing standard agents allows more women to live cancer-free for longer.


Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.